RU2007147925A - Замещенные тетрагидрохинолины - Google Patents
Замещенные тетрагидрохинолины Download PDFInfo
- Publication number
- RU2007147925A RU2007147925A RU2007147925/04A RU2007147925A RU2007147925A RU 2007147925 A RU2007147925 A RU 2007147925A RU 2007147925/04 A RU2007147925/04 A RU 2007147925/04A RU 2007147925 A RU2007147925 A RU 2007147925A RU 2007147925 A RU2007147925 A RU 2007147925A
- Authority
- RU
- Russia
- Prior art keywords
- aryl
- heteroaryl
- formula
- compounds
- hal
- Prior art date
Links
- 150000003530 tetrahydroquinolines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 37
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 5
- 125000003118 aryl group Chemical group 0.000 claims abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 3
- VIESAWGOYVNHLV-UHFFFAOYSA-N 1,3-dihydropyrrol-2-one Chemical class O=C1CC=CN1 VIESAWGOYVNHLV-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims abstract 2
- 229910052794 bromium Inorganic materials 0.000 claims abstract 2
- 229910052801 chlorine Inorganic materials 0.000 claims abstract 2
- 229910052731 fluorine Inorganic materials 0.000 claims abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 2
- 229910052740 iodine Inorganic materials 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 239000012453 solvate Substances 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000002207 metabolite Substances 0.000 claims 4
- 230000003211 malignant effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 claims 3
- 229960004448 pentamidine Drugs 0.000 claims 3
- 229940122440 HIV protease inhibitor Drugs 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 229940123468 Transferase inhibitor Drugs 0.000 claims 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 2
- 230000001028 anti-proliverative effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 239000002834 estrogen receptor modulator Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 239000004030 hiv protease inhibitor Substances 0.000 claims 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229940126601 medicinal product Drugs 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 229940075993 receptor modulator Drugs 0.000 claims 2
- 102000027483 retinoid hormone receptors Human genes 0.000 claims 2
- 108091008679 retinoid hormone receptors Proteins 0.000 claims 2
- 239000000849 selective androgen receptor modulator Substances 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 239000003558 transferase inhibitor Substances 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010024305 Leukaemia monocytic Diseases 0.000 claims 1
- 239000002841 Lewis acid Substances 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims 1
- 241000972349 Ocoa Species 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- JHXKRIRFYBPWGE-UHFFFAOYSA-K bismuth chloride Chemical compound Cl[Bi](Cl)Cl JHXKRIRFYBPWGE-UHFFFAOYSA-K 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 150000007517 lewis acids Chemical class 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 210000004324 lymphatic system Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000000394 mitotic effect Effects 0.000 claims 1
- 201000006894 monocytic leukemia Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- HZXJVDYQRYYYOR-UHFFFAOYSA-K scandium(iii) trifluoromethanesulfonate Chemical compound [Sc+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F HZXJVDYQRYYYOR-UHFFFAOYSA-K 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- AHZJKOKFZJYCLG-UHFFFAOYSA-K trifluoromethanesulfonate;ytterbium(3+) Chemical compound [Yb+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F AHZJKOKFZJYCLG-UHFFFAOYSA-K 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 abstract 1
- HVGIXFABNSOTLV-SQXDMPNOSA-N CC(N[C@@H](CC12)COC1c(cc(C(F)(F)F)cc1)c1NC2c1ccccc1)=O Chemical compound CC(N[C@@H](CC12)COC1c(cc(C(F)(F)F)cc1)c1NC2c1ccccc1)=O HVGIXFABNSOTLV-SQXDMPNOSA-N 0.000 description 1
- SWVCSTFUMNHBNG-ZAJCDATESA-N CC([C@H]1c2ccccc2)C1[Ar] Chemical compound CC([C@H]1c2ccccc2)C1[Ar] SWVCSTFUMNHBNG-ZAJCDATESA-N 0.000 description 1
- AYMHUVVJSRUGIE-HYJYAKSQSA-N CC[C@@H](CCC12)O[C@@H]1c(cc(cc1F)Br)c1N[C@H]2c1ccccc1 Chemical compound CC[C@@H](CCC12)O[C@@H]1c(cc(cc1F)Br)c1N[C@H]2c1ccccc1 AYMHUVVJSRUGIE-HYJYAKSQSA-N 0.000 description 1
- OMQSRPFOOSSBCJ-UHFFFAOYSA-N CN(C)CCC(NC(CC12)COC1c(cc(C(F)(F)F)cc1)c1NC2c1ccccc1)=O Chemical compound CN(C)CCC(NC(CC12)COC1c(cc(C(F)(F)F)cc1)c1NC2c1ccccc1)=O OMQSRPFOOSSBCJ-UHFFFAOYSA-N 0.000 description 1
- TUIRRCVJTAMXNM-UHFFFAOYSA-N CN(C)CCNC(C(CC12)COC1c(cc(C(F)(F)F)cc1)c1NC2c1ccccc1)=O Chemical compound CN(C)CCNC(C(CC12)COC1c(cc(C(F)(F)F)cc1)c1NC2c1ccccc1)=O TUIRRCVJTAMXNM-UHFFFAOYSA-N 0.000 description 1
- QBEDZOUXYLCUNR-UHFFFAOYSA-N CN(C)CCNC(NC(CC12)COC1c(cc(C(F)(F)F)cc1)c1NC2c1ccccc1)=O Chemical compound CN(C)CCNC(NC(CC12)COC1c(cc(C(F)(F)F)cc1)c1NC2c1ccccc1)=O QBEDZOUXYLCUNR-UHFFFAOYSA-N 0.000 description 1
- VEWSMTKRUHIAKE-UHFFFAOYSA-N CN(C)CCNC(OCC(CC12)COC1c(cc(C(F)(F)F)cc1)c1NC2c1ccccc1)=O Chemical compound CN(C)CCNC(OCC(CC12)COC1c(cc(C(F)(F)F)cc1)c1NC2c1ccccc1)=O VEWSMTKRUHIAKE-UHFFFAOYSA-N 0.000 description 1
- ZTIVPGXDZLAJMT-UHFFFAOYSA-N CNCC(CC12)OC1c(cc(C(F)(F)F)cc1)c1NC2c1ccccc1 Chemical compound CNCC(CC12)OC1c(cc(C(F)(F)F)cc1)c1NC2c1ccccc1 ZTIVPGXDZLAJMT-UHFFFAOYSA-N 0.000 description 1
- HXIMZOQNOMQIMW-VYJHHOQDSA-N CNCC1OC2c(cc(C(F)(F)F)cc3)c3N[C@H](C3CCCCC3)C2CC1 Chemical compound CNCC1OC2c(cc(C(F)(F)F)cc3)c3N[C@H](C3CCCCC3)C2CC1 HXIMZOQNOMQIMW-VYJHHOQDSA-N 0.000 description 1
- INHYNOZJAVXMJL-UHFFFAOYSA-N Cc1c2OCOc2ccc1 Chemical compound Cc1c2OCOc2ccc1 INHYNOZJAVXMJL-UHFFFAOYSA-N 0.000 description 1
- CKNVSFHTAJBYOD-UHFFFAOYSA-N Cc1cccc2c1OCCO2 Chemical compound Cc1cccc2c1OCCO2 CKNVSFHTAJBYOD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005027170.7 | 2005-06-13 | ||
| DE102005027170A DE102005027170A1 (de) | 2005-06-13 | 2005-06-13 | Substituierte Tetrahydrochinoline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007147925A true RU2007147925A (ru) | 2009-07-20 |
Family
ID=36699028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007147925/04A RU2007147925A (ru) | 2005-06-13 | 2006-05-17 | Замещенные тетрагидрохинолины |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7893082B2 (https=) |
| EP (1) | EP1891076B1 (https=) |
| JP (1) | JP5180070B2 (https=) |
| KR (1) | KR20080030015A (https=) |
| CN (2) | CN102010416A (https=) |
| AR (1) | AR054616A1 (https=) |
| AU (1) | AU2006312800B2 (https=) |
| BR (1) | BRPI0611613A2 (https=) |
| CA (1) | CA2611889C (https=) |
| DE (1) | DE102005027170A1 (https=) |
| ES (1) | ES2566729T3 (https=) |
| MX (1) | MX2007015782A (https=) |
| RU (1) | RU2007147925A (https=) |
| WO (1) | WO2007054138A1 (https=) |
| ZA (1) | ZA200800365B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005027168A1 (de) * | 2005-06-13 | 2006-12-14 | Merck Patent Gmbh | Tetrahydrochinoline |
| DE102005027169A1 (de) * | 2005-06-13 | 2006-12-14 | Merck Patent Gmbh | Tetrahydrochinolinderivate |
| DE102007013855A1 (de) * | 2007-03-20 | 2008-09-25 | Merck Patent Gmbh | Substituierte Tetrahydrochinoline |
| TW200934785A (en) | 2007-10-19 | 2009-08-16 | Schering Corp | Compounds for inhibiting KSP kinesin activity |
| EP2220067A2 (en) * | 2007-12-18 | 2010-08-25 | Merck Patent GmbH | Process for preparing tetrahydroquinoline derivatives |
| WO2019089412A1 (en) * | 2017-11-01 | 2019-05-09 | Merck Sharp & Dohme Corp. | Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
| EP4269392A4 (en) | 2020-12-25 | 2025-01-29 | Toray Industries, Inc. | TETRAHYDROQUINOLINE DERIVATIVE AND MEDICAL USE THEREOF |
| AU2023286251A1 (en) | 2022-06-24 | 2024-12-05 | Toray Industries, Inc. | Therapeutic agent or prophylactic agent for amyotrophic lateral sclerosis |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2273884A1 (en) * | 1996-12-18 | 1998-06-25 | Jose Serafin Mendoza | Combinatorial process for preparing hydrofuroquinoline libraries |
| US6288075B1 (en) * | 1998-02-26 | 2001-09-11 | Rhone-Poulenc Rorer S.A. | Thiazolo[5,4,3-ij]quinolines, preparation and medicines containing the same |
| US7250423B2 (en) | 2001-09-24 | 2007-07-31 | Chao-Jun Li | Methods for synthesizing heterocycles and therapeutic use of the heterocycles for cancers |
| WO2005016255A2 (en) * | 2003-07-16 | 2005-02-24 | Ligand Pharmaceuticals Incorporated | Substituted tetrahydroquinolines, phenylacetic acids and benzoic acids as hepatocyte nuclear factor 4 (hnf-4 ) modulator compounds |
| EP2033959B1 (de) * | 2003-12-20 | 2011-04-27 | Merck Patent GmbH | Tetrahydropyranochinolinderivate |
| SE0400285D0 (sv) * | 2004-02-10 | 2004-02-10 | Astrazeneca Ab | Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof |
| KR20070015598A (ko) * | 2004-04-28 | 2007-02-05 | 다케다 야쿠힌 고교 가부시키가이샤 | 융합 퀴놀린 유도체 및 이의 용도 |
| DE102005027168A1 (de) * | 2005-06-13 | 2006-12-14 | Merck Patent Gmbh | Tetrahydrochinoline |
| DE102005027169A1 (de) * | 2005-06-13 | 2006-12-14 | Merck Patent Gmbh | Tetrahydrochinolinderivate |
| CA2656064C (en) * | 2006-06-19 | 2013-11-05 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Polymorphic forms and process |
-
2005
- 2005-06-13 DE DE102005027170A patent/DE102005027170A1/de not_active Withdrawn
-
2006
- 2006-05-17 MX MX2007015782A patent/MX2007015782A/es active IP Right Grant
- 2006-05-17 CA CA2611889A patent/CA2611889C/en not_active Expired - Fee Related
- 2006-05-17 JP JP2008516155A patent/JP5180070B2/ja not_active Expired - Fee Related
- 2006-05-17 RU RU2007147925/04A patent/RU2007147925A/ru not_active Application Discontinuation
- 2006-05-17 KR KR1020087000901A patent/KR20080030015A/ko not_active Ceased
- 2006-05-17 EP EP06840909.3A patent/EP1891076B1/de not_active Not-in-force
- 2006-05-17 WO PCT/EP2006/004656 patent/WO2007054138A1/de not_active Ceased
- 2006-05-17 US US11/916,952 patent/US7893082B2/en not_active Expired - Fee Related
- 2006-05-17 CN CN2010105171785A patent/CN102010416A/zh active Pending
- 2006-05-17 ES ES06840909.3T patent/ES2566729T3/es active Active
- 2006-05-17 CN CNA200680021167XA patent/CN101198613A/zh active Pending
- 2006-05-17 AU AU2006312800A patent/AU2006312800B2/en not_active Ceased
- 2006-05-17 BR BRPI0611613-2A patent/BRPI0611613A2/pt not_active IP Right Cessation
- 2006-06-09 AR ARP060102412A patent/AR054616A1/es not_active Application Discontinuation
-
2008
- 2008-01-11 ZA ZA200800365A patent/ZA200800365B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20080030015A (ko) | 2008-04-03 |
| US20080194615A1 (en) | 2008-08-14 |
| ZA200800365B (en) | 2009-05-27 |
| EP1891076A1 (de) | 2008-02-27 |
| CN102010416A (zh) | 2011-04-13 |
| JP5180070B2 (ja) | 2013-04-10 |
| DE102005027170A1 (de) | 2006-12-14 |
| CA2611889C (en) | 2013-05-14 |
| US7893082B2 (en) | 2011-02-22 |
| EP1891076B1 (de) | 2016-01-27 |
| AR054616A1 (es) | 2007-07-04 |
| CA2611889A1 (en) | 2007-05-18 |
| ES2566729T3 (es) | 2016-04-15 |
| WO2007054138A1 (de) | 2007-05-18 |
| AU2006312800B2 (en) | 2011-08-25 |
| MX2007015782A (es) | 2008-02-22 |
| AU2006312800A1 (en) | 2007-05-18 |
| BRPI0611613A2 (pt) | 2010-09-21 |
| CN101198613A (zh) | 2008-06-11 |
| JP2008545803A (ja) | 2008-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2550350A1 (en) | 2-(hetero)aryl-substituted tetrahydroquinoline derivatives | |
| JP2007515419A5 (https=) | ||
| ES2644870T3 (es) | Derivados de oxatiazina como agentes antibacterianos y anticancerígenos | |
| US10774047B2 (en) | Dimeric quinacrine derivatives as autophagy inhibitors for cancer therapy | |
| RU92004336A (ru) | Водорастворимые производные камптотецина, способ их получения, фармацевтическая композиция, способ ингибирования энзима топоизомеразы, промежуточные продукты | |
| UA130084C2 (uk) | Імідазопіримідини як інгібітори eed і їх застосування | |
| JP2021152063A5 (https=) | ||
| RU2017145026A (ru) | Соединение, ингибирующее brk | |
| RU2014106966A (ru) | Пиразоло[3,4-с]пиридины и способы их применения | |
| RU99128053A (ru) | Новые циклические соединения диамина и содержащие их лекарственные средства | |
| SI9300591A (en) | Water soluble camptothecin derivatives | |
| RU2007147925A (ru) | Замещенные тетрагидрохинолины | |
| KR20190127576A (ko) | 암 세포의 이동과 침윤 억제를 통한 암 전이 억제제 | |
| US9867807B2 (en) | Compositions and methods for drug-sensitization or inhibition of a cancer cell | |
| RU2007116987A (ru) | Новые соединения | |
| MX2011010329A (es) | Derivados de quinoxalina y su uso para el tratamiento de trastornos de tumores benignos y malignos. | |
| RU2007125660A (ru) | Фенилпиперазиновые производные с сочетанием свойств неполного агонизма к рецепторам дофамина-d2 и ингибирования повторного поглощения серотонина | |
| JP2008545803A5 (https=) | ||
| JP7039579B2 (ja) | 抗癌剤としての４－アニリノ－キノリン化合物 | |
| RU2375354C2 (ru) | Производные 2-(гетеро)арил-замещенных тетрагидрохинолинов | |
| RU2007103300A (ru) | Тетрагидрохинолины | |
| JP2021534212A (ja) | 病的状態の治療における使用のための芳香族分子 | |
| JP7323238B2 (ja) | アミノキシ酸系抗がん幹細胞化合物およびその方法 | |
| KR102952770B1 (ko) | 타이람 유도체-구리 복합체 또는 이의 약학적으로 허용가능한 염을 포함하는 암 예방 또는 치료용 약학적 조성물 | |
| WO2015123392A1 (en) | Compositions and methods for inhibition of angiogenesis and lymphangiogenesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20120906 |